Abstract
Cancer is a leading cause of disease worldwide; however, nowadays many points of its initiation processes are unknown. In this chapter, we are focusing on the role of liquid biopsies in cancer detection and progression. CTCs are one of the main components of liquid biopsies, they represent a subset of tumor cells that have acquired the ability to disseminate from the primary tumor and intravasate to the circulatory system. The greatest challenge in the detection of CTCs is their rarity in the blood. Human blood consists of white blood cells (5–10 × 106/mL), red blood cells (5–9 × 109/mL), and platelets (2.5–4 × 108/mL); very few CTCs will be present even in patients with known metastatic disease, with often less than one CTC per mL of blood. CTCs are found in frequencies on the order of 1–10 CTCs per mL of whole blood in patients with metastatic disease, and it is reduced in half for non-metastatic stages. Therefore, accurate methodologies for their capture and analysis are really important. The main aim of the present chapter is to describe different methodologies for CTCs capturing and analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M et al (2014) EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget 5(17):7486–7497
Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3):373–382
Lianidou ES, Markou A, Strati A (2015) The role of CTCs as tumor biomarkers. Adv Exp Med Biol 867:341–367
Satelli A, Brownlee Z, Mitra A, Meng QH, Li S (2015) Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem 61(1):259–266
Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH et al (2015) EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. PLoS One 10(12):e0144535
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456
Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N et al (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10(4):1392–1400
Templeton AJ, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordan J et al (2014) Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat Rev 40(9):1048–1055
Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V (2014) Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemother Pharmacol 73(4):685–693
Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E et al (2013) Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res 33(9):3905–3910
Balic M, Lin H, Williams A, Datar RH, Cote RJ (2012) Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn 12(3):303–312
Miller MC, Doyle GV, Terstappen LW (2010) Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:617421
Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT et al (2013) A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods 64(2):137–143
Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F et al (2011) A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105(6):847–853
Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ et al (2011) 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13(1):203–213
van der Toom EE, Verdone JE, Gorin MA, Pienta KJ (2016) Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget 7:62754–62766
Harouaka RA, Nisic M, Zheng SY (2013) Circulating tumor cell enrichment based on physical properties. J Lab Autom 18(6):455–468
Alix-Panabières C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631
Schuur ER Rapid and simple isolation of circulating tumor cells for clinical and research applications using ScreenCell®. ScreenCell® devices: a flexible ctc platform
Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, Kuang Y et al (2011) A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 31(2):427–441
Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M et al (2003) Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 107(6):984–990
Bayarri-Lara C, Ortega FG, Cueto Ladrón de Guevara A, Puche JL, Ruiz Zafra J, de Miguel-Pérez D et al (2016) Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection. PLoS One 11(2):e0148659
Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E et al (2014) Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9(3):694–710
Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ et al (2011) Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res 17(22):7183–7193
Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X et al (2011) Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 25(2):59–68
Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R et al (2015) Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach. Mol Cancer Ther 14(10):2401–2408
Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C et al (2015) Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer 13(2):130–136
Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD et al (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9(8):997–1007
Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S et al (2016) Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 6:28910
Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P et al (2016) Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 16:168
Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13(3):R59
Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D et al (2015) Efficacy of Lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer. PLoS One 10(6):e0123683
Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D et al (2004) Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 90(2):443–448
Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E et al (2015) Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol 17(7):539–546
Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA (2013) Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 8(9):e75038
Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D et al (2015) Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 112(7):1166–1174
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038
Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD et al (2016) Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J. doi:10.1038/tpj.2016.62
Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C et al (2016) Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep 6:28010
Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M et al (2014) Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 14:423
Mostert B, Kraan J, Sieuwerts AM, van der Spoel P, Bolt-de V, Prager-van der Smissen WJ et al (2012) CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 319(1):49–55
Nadal R, Ortega FG, Salido M, Lorente JA, Rodríguez-Rivera M, Delgado-Rodríguez M et al (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133(10):2398–2407
Shi J, Li Y, Liang S, Zeng J, Liu G, Mu F et al (2016) Analysis of circulating tumor cells in colorectal liver metastasis patients before and after cryosurgery. Cancer Biol Ther 17(9):935–942
Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B et al (2014) ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem 60(10):1282–1289
Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ et al (2016) Prognostic significance of MUC-1 in circulating tumor cells in patients with metastatic pancreatic adenocarcinoma. Pancreas 45(8):1131–1135
Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O et al (2016) Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep 6:31726
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L et al (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9(9):1773–1782
Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I et al (2014) Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One 9(8):e103883
Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX et al (2015) Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol 9(4):850–860
Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S et al (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106(5):939–946
Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L et al (2015) Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 9(4):749–757
Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G et al (2014) TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res 16(5):445
Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L et al (2011) TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60(5):897–904
Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P et al (2015) PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer 113(8):1225–1233
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT et al (2015) Improved circulating tumor cell detection by a combined EpCAM and MCAM CellSearch enrichment approach in patients with breast cancer undergoing Neoadjuvant chemotherapy. Mol Cancer Ther 14(3):821–827
Gorges TM, Riethdorf S, von Ahsen O, Nastał YP, Röck K, Boede M et al (2016) Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget 7:34930–34941
Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H et al (2013) Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 73(7):2059–2069
Ueo H, Sugimachi K, Gorges TM, Bartkowiak K, Yokobori T, Müller V et al (2015) Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer 112(9):1519–1526
Abdallah EA, Fanelli MF, Souza E Silva V, Machado Netto MC, Gasparini Junior JL, Araújo DV et al (2016) MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. Int J Cancer 139(4):890–898
Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB et al (2012) ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 77(2):421–426
Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J et al (2016) Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget 7:59877–59891
Ortega FG, Lorente JA, Garcia Puche JL, Ruiz MP, Sanchez-Martin RM, de Miguel-Pérez D et al (2015) miRNA in situ hybridization in circulating tumor cells--MishCTC. Sci Rep 5:9207
Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 156(1):57–63
Kim MS, Sim TS, Kim YJ, Kim SS, Jeong H, Park JM et al (2012) SSA-MOA: a novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture (MOA) filter. Lab Chip 12(16):2874–2880
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS et al (2013) Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 3:1259
Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T et al (1998) Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 4(2):343–348
Gascoyne PR, Noshari J, Anderson TJ, Becker FF (2009) Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30(8):1388–1398
Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A et al (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11(10):3678–3685
Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R et al (2002) Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 49(4):150–158
Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM et al (2014) Size-selective collection of circulating tumor cells using Vortex technology. Lab Chip 14(1):63–77
Hur SC, Henderson-MacLennan NK, McCabe ER, Di Carlo D (2011) Deformability-based cell classification and enrichment using inertial microfluidics. Lab Chip 11(5):912–920
Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N et al (2013) Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A 110(41):16580–16585
Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R (2011) Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom 80(2):100–111
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14):4218–4224
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309
Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13(3):920–928
Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kühs U et al (2012) Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 32(8):3507–3513
Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E et al (2012) Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 14(4):R118
Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W et al (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106(10):3970–3975
Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ (2009) The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 4(3):281–283
Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397
Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239
Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC et al (2010) Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A 107(33):14524–14529
Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M et al (2013) Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol 6(5):528–538
Chen JF, Zhu Y, Lu YT, Hodara E, Hou S, Agopian VG et al (2016) Clinical applications of NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Theranostics 6(9):1425–1439
Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C et al (2012) Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One 7(4):e35976
Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P et al (2013) Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 335(1):225–231
Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P et al (2012) A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 41(4):1241–1250
Wu Y, Deighan CJ, Miller BL, Balasubramanian P, Lustberg MB, Zborowski M et al (2013) Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 64(2):169–182
Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A et al (2009) Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng 102(2):521–534
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E et al (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5(179):179ra147
Naume B, Borgen E, Tøssvik S, Pavlak N, Oates D, Nesland JM (2004) Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 6(3):244–252
Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35(5):463–474
Zuccolo J, Unruh TL, Deans JP (2009) Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red blood cells. BMC Immunol 10:30
Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene SB et al (2015) Analytical validation and capabilities of the Epic CTC platform:enrichment-freecirculating tumour cell detection and characterization. J Circulating Biomarkers 4, 3
Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE et al (2004) A rare-cell detector for cancer. Proc Natl Acad Sci U S A 101(29):10501–10504
Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P et al (2015) High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer 15:360
Alix-Panabières C, Pantel K (2015) Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Rev Mol Diagn 15(11):1411–1417
Tulley S, Zhao Q, Dong H, Pearl ML, Chen WT (2016) Vita-Assay™ method of enrichment and identification of circulating cancer cells/circulating tumor cells (CTCs). Methods Mol Biol 1406:107–119
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Alvarez Cubero, M.J., Lorente, J.A., Robles-Fernandez, I., Rodriguez-Martinez, A., Puche, J.L., Serrano, M.J. (2017). Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection. In: M. Magbanua, M., W. Park, J. (eds) Circulating Tumor Cells. Methods in Molecular Biology, vol 1634. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7144-2_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7144-2_24
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7143-5
Online ISBN: 978-1-4939-7144-2
eBook Packages: Springer Protocols